| ²é¿´: 489 | »Ø¸´: 0 | ||
17283904aaÒø³æ (³õÈëÎÄ̳)
|
[ÇóÖú]
¹òÇóH522ϸ°ûÔÙBALB/CÂãÊóÉíÉϽ¨Ä££¬³¤ÁË9ÌìÁË»¹²»¼ûÁö×Ó³¤³öÀ´£¬ÓÐ×ö¹ýÀàËÆµÄô
|
|
ÎÒÓõÄÊÇ´ÓATCCÐÂÂòµÄH522ϸ°û£¬ÔÙBALB/CÂãÊóÉíÉϽ¨Ä££¬½ÓÁËϸ°ûÖ®ºó³¤ÁË9ÌìÁË»¹²»¼ûÁö×Ó³¤³öÀ´£¬µÈµÄ¼±ËÀÈËÁË£¬ÓÐ×ö¹ýÀàËÆµÄǰ±²Ã´¡£¡£¡£Äܲ»ÄÜÌṩµã¾Ñ飬Íò·Ö¸Ðл~£¡£¡ ²Î¿¼ÎÄÏ× [1]. Desai, N., et al., Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 2006. 12(4): p. 1317-24. |
» ²ÂÄãϲ»¶
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
281Çóµ÷¼Á£¨0805£©
ÒѾÓÐ16È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Ìì´ó²ÄÁÏÓ뻯¹¤£¨085600£©×Ü·Ö338
ÒѾÓÐ4È˻ظ´
085700×ÊÔ´Óë»·¾³308Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çó²ÄÁϵ÷¼Á
ÒѾÓÐ8È˻ظ´
294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´













»Ø¸´´ËÂ¥